SEC Tracker
Get the app
MGRX · XBRL financial data

Mangoceuticals financial statements, every quarter

The same tables from 13 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (MGRX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024†Sep 30, 2024Feb 11, 2025Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue245244*214163133—1091688494*6869
Cost of revenue5253*213022—251929*810
Gross profit145—1477083—629051—2944
General and administrative1,944(3,620)*772851524—1,5421,245311657*1,054256
Total operating expenses1,9442,711*2,5152,2381,841—4,9155,3587,594415*3,1551,077
Operating income (loss)(1,799)(2,568)*(2,368)(2,169)(1,758)—(4,853)(5,268)(7,543)(368)*(3,126)(1,033)
Interest expense0*0*————(14)227620*——
Net income (loss)(1,799)(2,568)*(2,368)(2,391)(1,999)—(4,839)(5,416)(7,618)(2,770)*(3,403)(1,313)
Earnings per share, basic USD per share(0.11)—(0.10)(0.09)(0.99)—(1.29)(0.57)(0.69)—(0.22)(0.09)
Earnings per share, diluted USD per share(0.11)—(0.10)(0.09)(0.99)—(1.29)(0.57)(0.69)—(0.22)(0.09)
Weighted average shares, basic thousands of shares15,924—22,83326,1002,014—4,5939,98311,524—16,48217,120
Weighted average shares, diluted thousands of shares15,924—22,83326,1002,014—4,5939,98311,524—16,48217,120
  • † Share count changed about 1/12 in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (MGRX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024†Sep 30, 2024Feb 11, 2025Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents1,2377391549074306761014811,486175229
Inventory2219141413———————
Total current assets1,34381890518104—1771185981,547212246
Property and equipment, net102969033—322221
Right-of-use asset1331191059075—442811308294279
Total assets1,5961,05130115,23814,792—21,75420,84316,53216,09014,44914,173
Total current liabilities1592111,2121,3781,391—1,5031,6018048917381,398
Lease liability, non-current8265483012—————237251
Total liabilities2412761,2601,4081,404—1,5031,6018048919751,649
Accumulated deficit(8,660)(11,228)(13,596)(15,987)(17,986)—(25,940)(31,650)(37,878)(40,647)(44,051)(45,363)
Total stockholders' equity1,355775(958)13,83013,389—20,25219,24315,72915,20113,47612,526
Total liabilities and equity1,5961,05130115,23814,792—21,75420,84316,53216,09014,44914,173
Common shares outstanding (cover page) thousands of shares17,04023,62024,82029,9062,4875,16911,03410,53613,90716,96717,16721,567
  • † Share count changed about 1/12 in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (MGRX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024†Sep 30, 2024Feb 11, 2025Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(1,799)(2,568)*(2,368)(2,391)(1,999)—(4,839)(5,416)(7,618)(2,770)*(3,403)(1,313)
Stock-based compensation67*429*3851*109*—5151*1,100*(33)*1,09012*
Depreciation and amortization13*6*6(4)*0*—00*0*———
Net cash from operating activities(1,711)*(1,698)*(991)(1,577)*(1,166)*—(2,275)(1,256)*(1,241)*(1,078)*(1,311)(261)*
Purchases of property and equipment0*0*——————————
Net cash from investing activities0*0*——0*———————
Proceeds from issuing common stock0*1,200*180388*0*—655431*1,325*2,215*——
Net cash from financing activities0*1,200*2681,988*750*—2,2851,281*1,622*2,083*——
Net change in cash(1,711)*(498)*——————————
  • † Share count changed about 1/12 in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 8090 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 8090 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Mangoceuticals22969(261)*21.6M0.9 quarters 10-QJun 30, 2026
BioRestorative Therapies3,11323(3,808)25.5M0.9 quarters 10-QMar 31, 2026
Marpai1384,166(4,099)*26.8M0.0 quarters 10-QJun 30, 2026
Elite Health Systems1,3021,310(1,353)*28.5M1.0 quarters 10-QJun 30, 2026
Cryo Cell International1,4267,8241,142*8.1M— 10-QAug 31, 2026
IMAC Holdings4521(1,434)*3.8M0.0 quarters 10-QSep 30, 2025
Pacific Health Care Organization2,6531,513507*12.8M— 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.